Evaluation and management of pulmonary fibrosis in scleroderma
Author:
- 1 March 2002
- journal article
- review article
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 4 (2) , 108-112
Abstract
Pulmonary fibrosis causes significant morbidity and mortality in patients with scleroderma. Lung inflammation identifies patients at greater risk for decline in forced vital capacity and diffusing capacity for carbon monoxide. Factors that are increased in patients with scleroderma with lung fibrosis include connective tissue growth factor, KL-6, pulmonary surfactant-D, tissue inhibitor of metalloproteinase 2, monocyte chemotactic protein-1, macrophage inhibitory protein-1α, soluble interleukin-6 receptors, antiendothelial cell antibodies, and anti-DNA topoisomerase I antibodies. Potential mechanisms of lung damage in scleroderma include increased production of profibrotic type 2 cytokines and abnormal signaling by thrombin of tenascin-C production by lung fibroblasts, with protein kinase Cε as an intermediate in the signaling pathway. Treatment of scleroderma lung disease with cyclophosphamide may have a beneficial effect on pulmonary function and survival. Lung transplantation provides a therapeutic option for patients with scleroderma with end-stage lung disease.Keywords
This publication has 35 references indexed in Scilit:
- Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in sclerodermaArthritis & Rheumatism, 2000
- Th2 cells as effectors in postirradiation pulmonary damage preceding fibrosis in the ratInternational Journal of Radiation Biology, 1999
- Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosisArthritis & Rheumatism, 1997
- Costimulation of Fibroblast Collagen and Transforming Growth Factor β1 Gene Expression by Monocyte Chemoattractant Protein-1 via Specific ReceptorsJournal of Biological Chemistry, 1996
- Skewing of the CDS + T-cell repertoire in the lungs of patients with systemic sclerosisHuman Immunology, 1996
- Severe restrictive lung disease in systemic sclerosisArthritis & Rheumatism, 1994
- Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4.Journal of Clinical Investigation, 1992
- Human recombinant interleukin-4 induces proliferation and interleukin-6 production by cultured human skin fibroblastsClinical Immunology and Immunopathology, 1992
- Immunogenetic prediction of pulmonary fibrosis in systemic sclerosisThe Lancet, 1991
- Fibroblast chemotaxis induction by human recombinant interleukin-4. Identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences 70-88 and 89-122.Journal of Clinical Investigation, 1991